IDEXX Laboratories, Inc. Stock
Equities
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 693.85 USD | +0.41% |
|
-3.01% | +2.56% |
| 16/01 | IDEXX Laboratories, Inc. Launches ImageVue DR50 Plus | CI |
| 16/01 | IDEXX Laboratories, Inc. Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs | CI |
| Capitalization | 55.4B 47.12B 43.68B 40.82B 76.09B 5,090B 80.65B 499B 198B 2,403B 208B 204B 8,743B | P/E ratio 2025 * |
53.7x | P/E ratio 2026 * | 48x |
|---|---|---|---|---|---|
| Enterprise value | 56.18B 47.78B 44.29B 41.39B 77.15B 5,162B 81.78B 506B 201B 2,437B 211B 206B 8,865B | EV / Sales 2025 * |
13.1x | EV / Sales 2026 * | 12x |
| Free-Float |
75.42% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: IDEXX Laboratories, Inc.
| 1 day | +0.41% | ||
| 1 week | -3.01% | ||
| Current month | +2.56% | ||
| 1 month | +1.69% | ||
| 3 months | +8.65% | ||
| 6 months | +28.33% | ||
| Current year | +2.56% |
| 1 week | 681 |  | 709.24 |
| 1 month | 661.89 | | 726.41 |
| Current year | 661.89 | | 726.41 |
| 1 year | 356.14 | | 769.98 |
| 3 years | 356.14 | | 769.98 |
| 5 years | 317.06 | | 769.98 |
| 10 years | 63.48 | | 769.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 65 | 28/06/2019 | |
Andrew Emerson
DFI | Director of Finance/CFO | 43 | 01/03/2025 |
Martin Smith
COO | Chief Operating Officer | 58 | 01/01/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
M. Szostak
BRD | Director/Board Member | 75 | 16/07/2012 |
| Director/Board Member | 65 | 23/10/2019 | |
| Director/Board Member | 64 | 15/07/2013 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.75% | 1.59% | 26 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.41% | -3.01% | +60.49% | +39.85% | 55.4B | |
| Average | +0.41% | -3.01% | +60.49% | +39.85% | 55.4B | |
| Weighted average by Cap. | +0.41% | -3.01% | +60.49% | +39.85% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.29B 3.64B 3.38B 3.16B 5.88B 394B 6.24B 38.61B 15.33B 186B 16.07B 15.74B 676B | 4.66B 3.96B 3.67B 3.43B 6.4B 428B 6.79B 42B 16.67B 202B 17.48B 17.12B 736B |
| Net income | 1.05B 889M 824M 770M 1.44B 96.07B 1.52B 9.42B 3.74B 45.36B 3.92B 3.84B 165B | 1.16B 983M 912M 852M 1.59B 106B 1.68B 10.42B 4.14B 50.16B 4.34B 4.25B 182B |
| Net Debt | 776M 660M 612M 572M 1.07B 71.33B 1.13B 6.99B 2.78B 33.68B 2.91B 2.85B 123B | 439M 374M 346M 324M 603M 40.37B 640M 3.96B 1.57B 19.06B 1.65B 1.61B 69.34B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 693.85 $ | +0.41% | 279,293 |
| 22/01/26 | 691.05 $ | -0.78% | 453,761 |
| 21/01/26 | 696.46 $ | +1.52% | 556,558 |
| 20/01/26 | 686.02 $ | -4.10% | 560,688 |
| 16/01/26 | 715.37 $ | +0.46% | 532,116 |
Delayed Quote Nasdaq, 24 January 2026 at 08:00 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- IDXX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition